Compare KBDC & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | VIR |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.8M | 1.0B |
| IPO Year | 2018 | 2019 |
| Metric | KBDC | VIR |
|---|---|---|
| Price | $13.66 | $9.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $15.50 | ★ $19.63 |
| AVG Volume (30 Days) | 424.4K | ★ 4.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 13.92% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 1.67 | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $193.84 | N/A |
| Revenue Next Year | $9.00 | $925.73 |
| P/E Ratio | $8.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.06 | $4.16 |
| 52 Week High | $16.98 | $10.91 |
| Indicator | KBDC | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 63.68 |
| Support Level | $13.54 | $4.95 |
| Resistance Level | $15.25 | $10.91 |
| Average True Range (ATR) | 0.35 | 0.68 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 50.60 | 68.59 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.